Summary
Foundation Medicine Inc (Foundation Medicine), a subsidiary of F. Hoffmann-La Roche Ltd is a healthcare products provider that offers cancer care solutions. The company offers molecular information and cancer research programs. It offers clinical products which include FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas and others. It also offers additional materials, services, and real-time data through its technology products. The company partners with biotech and pharmaceutical companies to develop targeted cancer therapies and active clinical trials. Foundation Medicine is headquartered in Cambridge, Massachusetts, the US.
Foundation Medicine Inc (FMI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 17
Partnerships 18
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 18
Epizyme Enters into Agreement with Foundation Medicine 19
Foundation Medicine Enters into Agreement with AstraZeneca 20
Foundation Medicine Partners with AstraZeneca 21
Foundation Medicine Enters into Agreement with Mirati Therapeutics 22
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 23
Roche Enters into R&D Agreement with Foundation Medicine 24
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 25
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 26
Foundation Medicine Expands Co-Development Agreement With Novartis 27
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 28
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 29
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 30
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 31
Equity Offering 32
Foundation Medicine Raises USD250 Million in Private Placement of Shares 32
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 33
Foundation Medicine Completes IPO Of Shares For US$122 Million 34
Acquisition 35
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 35
Foundation Medicine Inc - Key Competitors 37
Foundation Medicine Inc - Key Employees 38
Foundation Medicine Inc - Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Aug 01, 2017: Foundation Medicine Announces 2017 Second Quarter Results and Recent Highlights 40
May 09, 2017: Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights 42
Feb 22, 2017: Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook 44
Jan 09, 2017: Foundation Medicine Reports Preliminary 2016 Results 45
Nov 02, 2016: Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights 47
Aug 02, 2016: Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights 49
May 03, 2016: Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights 51
Feb 23, 2016: Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook 52
Jan 11, 2016: Foundation Medicine Reports Preliminary 2015 Results and Provides 2016 Business Outlook, including Commercial Launch of its ctDNA Assay 53
Corporate Communications 54
Jan 06, 2017: Foundation Medicine Announces Executive Leadership Transition 54
Oct 27, 2016: Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors 55
Product News 56
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 56
Other Significant Developments 58
Feb 25, 2016: Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59
List of Tables
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Foundation Medicine Raises US$56 Million In Series B Financing 13
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 15
Foundation Medicine Raises US$10 Million In Venture Financing 17
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 18
Epizyme Enters into Agreement with Foundation Medicine 19
Foundation Medicine Enters into Agreement with AstraZeneca 20
Foundation Medicine Partners with AstraZeneca 21
Foundation Medicine Enters into Agreement with Mirati Therapeutics 22
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 23
Roche Enters into R&D Agreement with Foundation Medicine 24
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 25
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 26
Foundation Medicine Expands Co-Development Agreement With Novartis 27
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 28
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 29
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 30
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 31
Foundation Medicine Raises USD250 Million in Private Placement of Shares 32
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 33
Foundation Medicine Completes IPO Of Shares For US$122 Million 34
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 35
Foundation Medicine Inc, Key Competitors 37
Foundation Medicine Inc, Key Employees 38
Foundation Medicine Inc, Other Locations 39
List of Figures
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Foundation Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Foundation Medicine Inc, Medical Devices Deals, 2011 to YTD 2017 10
